UniProt P29320 · PDB · AlphaFold · Substrate: pEY + Mn · Clone: cytoplasmichigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dasatinib | 100.0% | 0.0% | 87.97 | 0.699 |
| 2 | Ponatinib | 97.8% | 2.2% | 78.23 | 0.534 |
| 3 | Bosutinib | 95.5% | 4.5% | 87.22 | 0.555 |
| 4 | Ripretinib | 87.7% | 12.3% | 92.95 | 0.674 |
| 5 | Repotrectinib | 86.8% | 13.2% | 84.21 | 0.608 |
| 6 | Cabozantinib | 86.2% | 13.8% | 92.73 | 0.751 |
| 7 | Nilotinib | 76.0% | 24.0% | 96.49 | 0.765 |
| 8 | Tivozanib | 69.4% | 30.6% | 92.42 | 0.673 |
| 9 | Crizotinib | 61.5% | 38.5% | 91.39 | 0.581 |
| 10 | Erdafitinib | 54.5% | 45.5% | 95.71 | 0.737 |
| 11 | Fostamatinib | 54.0% | 46.0% | 96.74 | 0.613 |
| 12 | Vandetanib | 53.0% | 47.0% | 95.74 | 0.723 |
| 13 | Canertinib | 47.2% | 52.8% | 96.49 | 0.671 |
| 14 | Regorafenib | 31.1% | 68.9% | 95.99 | 0.719 |
| 15 | Afatinib | 26.1% | 73.9% | 98.50 | 0.709 |
| 16 | Dacomitinib | 23.4% | 76.6% | 97.99 | 0.664 |
| 17 | Nintedanib | 22.1% | 77.9% | 90.23 | 0.608 |
| 18 | Gilteritinib | 20.3% | 79.7% | 88.97 | 0.506 |
| 19 | Entrectinib | 19.3% | 80.7% | 93.69 | 0.671 |
| 20 | Alectinib | 19.0% | 81.0% | 95.49 | 0.651 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.08
- Epithelial log2(TPM+1): 0.32
- Fold change: 0.77
- Status: No significant change
High-confidence drugs
- Dasatinib — inh 100.0% · KISS 42.28
- Bosutinib — inh 95.5% · KISS 30.52
- Cabozantinib — inh 86.2% · KISS 30.42
Selectivity landscape vs inhibition on EPHA3
Each point is one of the 92 approved drugs; color = inhibition % on EPHA3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…